Biomedical Engineering Reference
In-Depth Information
alpha-MSH and gamma3-MSH) fused to latency-associated
peptides results in improved anti-inflammatory therapeutics.
Ann Rheum Dis 17, 143-149.
83. Fingleton B. (2006) Matrix metalloproteinases: roles in can-
cer and metastasis. Front Biosci. 11, 479-491.
84. Ii M, Yamamoto H, Adachi Y, Maruyama Y, Shinomura Y.
(2006) Role of matrix metalloproteinase-7 (matrilysin) in
human cancer invasion, apoptosis, growth, and angiogenesis.
Exp. Biol. Med. (Maywood) 231, 20-27.
85. Amalinei C, Caruntu ID, Giusca SE, Balan RA. (2010) Matrix
metalloproteinases involvement in pathologic conditions.
Rom. J. Morphol. Embryol. 51, 215-228.
86. Piper PJ, Said SI, Vane JR. (1970) Effects on smooth muscle
preparations of unidentified vasoactive peptides from intes-
tine and lung. Nature 225, 1144-1146.
87. Said SI, Mutt V. (1970) Polypeptide with broad biological
activity:
aggrecanase (ADAMTS) activity is responsible for the cata-
bolic turnover and loss of whole aggrecan whereas other
protease activity is required for C-terminal processing in vivo.
Biochem. J. 358, 615-626.
97. Fosang AJ, Rogerson FM, East CJ, Stanton H. (2008)
ADAMTS-5: the story so far. Eur. Cell Mater. 15, 11-26.
98. Sandy JD. (2006) A contentious issue finds some clarity: on
the independent and complementary roles of aggrecanase
activity and MMP activity in human joint aggrecanolysis.
Osteoarthritis Cartilage 14, 95-100.
99. Hills R, Mazzarella R, Fok K, Liu M, Nemirovskiy O, Leone
J, et al. (2007) Identification of an ADAMTS-4 cleavage
motif using phage display leads to the development of
fluorogenic peptide substrates and reveals matrilin-3 as a
novel substrate. J. Biol. Chem. 282, 11101-11109.
100. Gentry LE, Nash BW. (1990) The pro domain of pre-pro-
transforming growth factor beta 1 when independently
expressed is a functional binding protein for the mature
growth factor. Biochemistry 29, 6851-6857.
101. Bottinger EP, Factor VM, Tsang ML, Weatherbee JA, Kopp
JB, Qian SW, et al. (1996) The recombinant proregion of
transforming growth factor beta1 (latency-associated pep-
tide) inhibits active transforming growth factor beta1
in transgenic mice. Proc. Natl. Acad. Sci. U S A 93,
5877-5882.
102. Vodovotz Y, Chesler L, Chong H, Kim SJ, Simpson JT,
DeGraff W, et al. (1999) Regulation of transforming
growth factor beta1 by nitric oxide. Cancer Res. 59,
2142-2149.
103. McMahon GA, Dignam JD, Gentry LE. (1996) Structural
characterization of the latent complex between transforming
growth factor beta 1 and beta 1-latency-associated peptide.
Biochem. J. 313, 343-351.
104. Ali NA, Gaughan AA, Orosz CG, Baran CP, McMaken S,
Wang Y, et al. (2008) Latency associated peptide has in vitro
and in vivo immune effects independent of TGF-beta1. PLoS
One 3, e1914.
105. Holle L, Song W, Holle E, Wei Y, Li J, Wagner TE, et al.
(2009) In vitro- and in vivo-targeted tumor lysis by an
MMP2 cleavable melittin-LAP fusion protein. Int. J. Oncol.
35, 829-835.
106. Holle L, Song W, Holle E, Wei Y, Wagner T, Yu X. (2003) A
matrix metalloproteinase 2 cleavable melittin/avidin conju-
gate specifically targets tumor cells in vitro and in vivo. Int. J.
Oncol. 22, 93-98.
107. Leuschner C, Hansel W. (2004) Membrane disrupting lytic
peptides for cancer treatments. Curr. Pharm. Des. 10,
2299-2310.
isolation from small
intestine. Science 169,
1217-1218.
88. Ganea D, Delgado M. (2002) Vasoactive intestinal peptide
(VIP) and pituitary adenylate cyclase-activating polypeptide
(PACAP) as modulators of both innate and adaptive immu-
nity. Crit. Rev. Oral Biol. Med. 13, 229-237.
89. Henning RJ, Sawmiller DR. (2001) Vasoactive intestinal
peptide: cardiovascular effects. Cardiovasc. Res. 49, 27-37.
90. Lipton JM, Ceriani G, Macaluso A, McCoy D, Carnes K,
Biltz J, et al. (1994) Antiinflammatory effects of the neuro-
peptide alpha-MSH in acute, chronic, and systemic inflam-
mation. Ann. N. Y. Acad. Sci. 741, 137-148.
91. Stack MS, Gray RD. (1989) Comparison of vertebrate colla-
genase and gelatinase using a new fluorogenic substrate
peptide. J. Biol. Chem. 264, 4277-4281.
92. Ye QZ, Johnson LL, Yu AE, Hupe D. (1995) Reconstructed
19 kDa catalytic domain of gelatinase A is an active protein-
ase. Biochemistry 34, 4702-4708.
93. Peng KW, Morling FJ, Cosset FL, Murphy G, Russell SJ.
(1997) A gene delivery system activatable by disease-
associated matrix metalloproteinases. Hum. Gene. Ther. 8,
729-738.
94. Vessillier S, Adams G, Chernajovsky Y. (2004) Latent cyto-
kines: development of novel cleavage sites and kinetic anal-
ysis of their differential sensitivity to MMP-1 and MMP-3.
Protein Eng. Des. Sel. 17, 829-835.
95. Tortorella MD, Burn TC, Pratta MA, Abbaszade I, Hollis JM,
Liu R, et al. (1999) Purification and cloning of aggrecanase-1:
a member of the ADAMTS family of proteins. Science 284,
1664-1666.
96. Sandy JD, Verscharen C. (2001) Analysis of aggrecan in
human knee cartilage and synovial fluid indicates that
Search WWH ::
Custom Search